Phase 3 suppliers will demonstrate the clinical performance of the developed prototype following the protocol approved in Phase 2 and authorised by the relevant ethical committees and all the other authorising entities/agencies.
During this phase, oncNGS developed porotype will be tested in the clinical setting using real clinical samples at buyers sites.
At the end of Phase 3, if the Buyers are satisfied with the results they will apply their best effort to ensure that such products are procured by means of the correspondent commercial procurement procedures, that will be opened to all the interested companies.
Overall duration: 18 months
Execution : 15 months